Advances in Clinical and Experimental Medicine
2016, vol. 25, nr 5, September-October, p. 821–828
Publication type: original article
The Effects of Anti-CD3/CD28 Coated Beads and IL-2 on Expanded T Cell for Immunotherapy
1 Graduate Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand
2 Center for Emerging and Neglected Infectious Diseases, Mahidol University, Nakhon Pathom, Thailand
3 Office for Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
4 Department of Transfusion Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand
Background. The activation of peripheral blood mononucleated cells (PBMCs) with anti-CD3/CD28-coated magnetic beads promotes intrinsic resistance to HIV as well as cell expansion.
Objectives. The aim of this study was to define an optimal cell isolation protocol for the expansion of PBMCs using anti-CD3/CD28-coated bead stimulation, with the ultimate goal of using these cells for adoptive therapy.
Material and Methods. PBMCs were isolated from healthy donor blood samples. To determine the effect of varying the bead-to-cell ratios on the expansion rate and phenotypic characterization of the expanded cells, one million PBMCs were stimulated by anti-CD3/CD28-coated beads at bead-to-cell ratios of 0.1 : 1, 0.5 : 1 and 1.0 : 1 in the presence of 100 U/mL exogenous IL-2; also, one million PBMCs were stimulated by anti-CD3/CD28-coated beads at a bead-to-cell ratio of 0.5 : 1 in the presence of varying concentrations of IL-2 (20, 100 and 1000 U/mL). Cell expansion was carried out for three weeks. The cell numbers, cell viability and phenotypic characterization were determined by trypan blue exclusion and flow cytometry.
Results. The initial experiments showed no difference in the expansion rate from cells grown with the three different bead-to-cell ratios. PBMCs can be expanded up to 1000-fold at a 0.5 : 1 bead-to-cell ratio after three weeks of cell expansion with a high viability (90%). Furthermore, in the presence of 100 U/mL IL-2, the percentages of CD3-CD16+CD56+ cells showed marked increases.
Conclusion. The results demonstrate that PBMCs were stimulated with anti-CD3/CD28-coated beads. This method may provide an alternative for driving T cell expansion, which may be very useful in adoptive immunotherapy.
PBMCs, IL-2, anti-CD3/CD28, cell expansion
- Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990, 248, 1349–1356.
- Smith-Garvin JE, Koretzky GA, Jordan MS: T cell activation. Annu Rev Immunol 2009, 27, 591–619.
- Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA: CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol 1996, 157, 3909–3917.
- Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M: Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother 2004, 27, 405–418.
- Onlamoon N, Hudson K, Bryan P, Mayne AE, Bonyhadi M, Berenson R, Sundstrom BJ, Bostik P, Ansari AA, Villinger F: Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy. J Med Primatol 2006, 35, 178–193.
- Trickett AE, Kwan YL, Cameron B, Dwyer JM: Ex vivo expansion of functional T lymphocytes from HIV-infected individuals. J Immunol Methods 2002, 262, 71–83.
- Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, Van Epps DE, Hardwick RA, June CH: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998, 7, 437–448.
- Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993, 151, 2444–2452.
- Bachmann MF, Oxenius A: Interleukin 2: From immunostimulation to immunoregulation and back again. EMBO 2007, Rep. 8, 1142–1148.
- Lai YP, Lin CC, Liao WJ, Tang CY, Chen SC: CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses. PLoS One 2009, 4, e7766.
- Berhanu D, Mortari F, De Rosa SC, Roederer M: Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J Immunol Methods 2003, 279, 199–207.
- De Paoli P, Reitano M, Battistin S, Castiglia C, Santini G: Enumeration of human lymphocyte subsets by monoclonal antibodies and flow cytometry: A comparative study using whole blood or mononuclear cells separated by density gradient centrifugation. J Immunol Methods 1984, 72, 349–353.
- Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CM: Low-strength T-cell activation promotes Th17 responses. Blood 2010, 116, 4829–4837.
- Deenick EK, Gett AV, Hodgkin PD: Stochastic model of T cell proliferation: A calculus revealing IL-2 regulation of precursor frequencies, cell cycle time, and survival. J Immunol 2003, 170, 4963–4972.
- Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood 2006, 108, 600–608.
- Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D: Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999, 11, 281–288.
- El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, Janbazian L, Fonseca S, van Grevenynghe J, YassineDiab B, Sekaly RP, Haddad EK: T-cell exhaustion in HIV infection. Curr. HIV/AIDS 2008, Rep. 5, 13–19.
- Paranjape RS: Immunopathogenesis of HIV infection. Indian J Med Res 2005, 121, 240–255.